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Abstract
Antiretroviral-based pre-exposure HIV interventions may soon be rolled out in resource-
constrained Sub-Saharan African countries, but rollout plans have yet to be designed. Here we use 
geospatial modeling and optimization techniques to compare two rollout plans for ARV-based 
microbicides in South Africa: a utilitarian plan that minimizes incidence by using geographic 
targeting, and an egalitarian plan that maximizes geographic equity in access to interventions. We 
find significant geographic variation in the efficiency of interventions in reducing HIV 
transmission, and that efficiency increases disproportionately with increasing incidence. The 
utilitarian plan would result in considerable geographic inequity in access to interventions, but (by 
exploiting geographic variation in incidence) could prevent ~40% more infections than the 
egalitarian plan. Our results show that the geographic resource allocation decisions made at the 
beginning of a rollout, and the location where the rollout is initiated, will be crucial in determining 
the success of interventions in reducing HIV epidemics.
Introduction
Ameliorating the HIV pandemic in resource-constrained settings is one of the greatest 
challenges facing the global community in the 21st Century. Worldwide ~34 million 
individuals are infected with HIV; and in Sub-Saharan Africa alone, 3 million new 
infections occur annually 1. Results from recent clinical trials indicate that prevention tools 
based on antiretrovirals (ARVs) could be effective in controlling the pandemic. ARV-based 
*Corresponding author: sblower@mednet.ucla.edu.
#Current Affiliation: Department of Mathematics and Computer Science, Xavier University, 3800 Victory Parkway, Cincinnati, OH 
45207
Author Contributions All authors contributed to the design of the project, the formulation and analysis of the models, the 
interpretation of the results, and the writing of the manuscript. DJG and BGW implemented and simulated the mathematical models. 
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for 
Disease Control and Prevention.
Conflict of Interest We declare that we have no conflicts of interest.
NIH Public Access
Author Manuscript
Nat Commun. Author manuscript; available in PMC 2015 June 02.
Published in final edited form as:






















pre-exposure prophylaxis (PrEP) 2–4, ARV-based microbicides 5, and providing ARVs to 
the HIV-positive partner in a discordant couple 6 have been shown to provide partial 
protection against HIV infection. Interventions, based on these tools, may soon be rolled out 
in resource-constrained countries in Sub-Saharan Africa. When this occurs, governments 
will have to decide how to allocate their available resources. Allocation decisions will be 
based on a consideration of multiple factors, including their ethical implications. The World 
Health Organization has recommended considering four ethical principles when deciding 
how to allocate scarce resources: the egalitarian principle of equity in access to the resource, 
the utilitarian principle of maximizing overall societal benefits, the Maximin principle 
(prioritizing the least advantaged individuals), and the principle of justice as reciprocity or 
compensation 7,8. A government, operating under resource constraints, may choose to make 
resource allocation decisions based on one or more of these principles.
Here we use geospatial modeling to compare two rollout plans: one is based on the 
egalitarian principle and the other on the utilitarian principle. Both plans use the same 
amount of resources. The objective of the egalitarian plan is to maximize countrywide 
equity in access to the available prevention resources. The objective of the utilitarian plan is 
to maximize the number of HIV infections prevented (IP). We compare the rollout plans, 
under resource constraints, in terms of: (i) the geographic resource allocation strategy 
(GRAS) that is needed for implementation, (ii) the optimal location to begin the rollout, and 
(iii) the number of HIV IP. In addition we identify significant geographic variation in the 
efficiency of interventions in reducing HIV transmission, and a nonlinear relationship 
linking efficiency with the pre-intervention HIV incidence rate. We discuss the implications 
of our results for rolling out ARV-based microbicides, and other ARV-based pre-exposure 
interventions, in Sub-Saharan Africa.
Women are disproportionally affected by the HIV epidemic in Sub-Saharan Africa. 
Therefore we chose to focus our analyses on the potential rollout of interventions using 
ARV-based microbicides. We evaluate rollout plans for South Africa as we use data from 
the landmark trial, CAPRISA 004, which was conducted in KwaZulu-Natal province in 
20105,9. CAPRISA 004 showed that a tenofovir-based microbicide gel with coital dosing 
was partially effective in preventing HIV infection. The microbicide was also found to be 
partially effective in protecting against herpes simplex virus type 2 (HSV-2). After the 
success of CAPRISA 004 the South African Government began a confirmatory trial, FACTS 
001, in 2011. This is a nine-site trial that uses the same microbicide and coital dosing as in 
CAPRISA 004. The plan is to enroll over 2,000 women; results will be available at the end 
of 2014. FACTS 001 is a phase III licensure study. If it is at least as successful as the 
CAPRISA 004 trial the microbicide could receive regulatory approval by 2015. To prepare 
for a potential rollout of this microbicide, the South African Government’s Technology 
Innovation Agency (TIA) has made a license agreement with CONRAD, the organization 
that supervised the manufacture of the microbicide for CAPRISA 004. This agreement 
grants TIA the rights, if the microbicide receives regulatory approval, to manufacture and 
distribute the microbicide in Africa.
The average prevalence of HIV in South Africa is 17%, but prevalence ranges from 8% in 
women (6% in men) in the Western Cape to 26% in women (20% in men) in KwaZulu-
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Natal province, see Supplementary Table 1 for HIV prevalence levels in the remaining 
provinces. Due to the significant geographic heterogeneity in prevalence we use geospatial 
modeling to compare the utilitarian with the egalitarian rollout plan. We linked two types of 
models: a geospatial resource allocation (RA) model and a geospatial meta-population 
transmission (MT) model of coupled HIV and HSV-2 epidemics. Each population in the 
model represents the population in one of the nine provinces in South Africa, and the meta-
population represents the population of the entire country. The model includes the spatial 
demographics of South Africa, the within-country geographic variation in HIV prevalence, 
the province-specific rollout of treatment (with coverage increasing from 2004 onwards, see 
Supplementary Fig. 1) and geographic heterogeneity in sexual behavior; see Methods.
Results
Calibrating the geospatial MT model
Our gender-stratified estimates of HIV incidence rates and prevalence levels, obtained from 
the calibration procedure (see Methods), show significant geographic variation throughout 
South Africa. Province-specific gender-stratified estimates of HIV incidence rates, in terms 
of the median value and Inter-Quartile-Range (IQR), are given in Supplementary Table 2. 
Province-specific gender-stratified estimates of both HIV and HSV-2 prevalence levels are 
shown in Supplementary Fig. 2.
Multivariate Sensitivity Analysis of the Geospatial MT model
The results of the multivariate sensitivity analysis of the geospatial MT model are presented 
as three-dimensional response hypersurfaces (Fig. 1); the colors in the hypersurfaces show 
the percent reduction in transmission in KwaZulu-Natal, due to microbicides, over a decade. 
Fig. 1 shows the impact of microbicides as a function of their effectiveness in protecting 
against HIV infection (Y-axis) and the coverage of the intervention (X-axis). Fig. 1A shows 
the reduction in HIV transmission for women, and Fig. 1B the reduction in HIV 
transmission for men. Fig. 1C shows the reduction in HSV-2 transmission for women, and 
Fig. 1D the reduction in HSV-2 transmission for men. The response hypersurfaces show 
that, over a decade, the maximum reduction in HIV transmission in women could be as high 
as ~60%; however this would only be possible if the effectiveness of the microbicide was 
high (~70%) and coverage reached ~90% (Fig. 1A). Under these conditions, HSV-2 
transmission in women would be reduced by ~30% (Fig. 1C). Men would also benefit from 
microbicides, but to a lesser extent; their HIV transmission would be reduced by a maximum 
of 25% over a decade (Fig. 1B) and their HSV-2 transmission by a maximum of 10% (Fig. 
1D). The reduction in HSV-2 transmission depends on microbicide coverage, but does not 
increase with an increase in effectiveness (over the range from 15% to 75%) of the 
microbicide against HIV (Fig. 1C and 1D).
Scenario Analyses of the Geospatial MT model
The results from the scenario analyses show the effect of microbicide-based interventions in 
KwaZulu-Natal on reducing both HIV transmission (Fig. 2A for women, Fig. 2B for men) 
and HSV-2 transmission (Fig. 2C for women, Fig. 2D for men). Coverage is 90% in 
scenarios shown as solid lines and 60% in scenarios shown as dotted lines. Red, green and 
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blue lines represent scenarios where adherence is low (red), moderate (green) or high (blue); 
the corresponding effectiveness of the microbicide against HIV infection is 28%, 38%, and 
54%. In all scenarios, regardless of adherence, the effectiveness of the microbicide against 
HSV-2 infection is 51%. See Methods for the definitions of adherence and effectiveness, 
and their relation to data from the CAPRISA 004 trial.
The percentage of HIV IP in women increases quickly for ~3 years; it then continues to 
increase but at a slower rate (Fig. 2A). The greater the effectiveness of the microbicide 
against HIV and/or the higher the coverage the more HIV infections are prevented (Fig. 2A). 
The percentage of HIV IP in men continues to steadily increase over a decade, but is always 
significantly lower than in women (Fig. 2B). Reduction in HIV transmission in men is a 
delayed effect because of the indirect benefit of microbicides. The percent reduction in 
HSV-2 transmission in women increases quickly for 2–3 years, but then plateaus (Fig. 2C). 
The higher the coverage, the more HSV-2 IP; however the degree of effectiveness against 
HIV (over the range: ~15% to ~75%) has virtually no effect on the number of HSV-2 IP 
(Figs 2C and 2D). The percentage of HSV-2 IP in men continues to steadily increase over a 
decade, but is always significantly lower than in women (Fig. 2D).
The effect of the HSV-2 epidemic on increasing HIV transmission in South Africa is due to 
the high prevalence of HSV-2 (~60% in women and ~40% in men), and a reduction in 
HSV-2 transmission would not lead to a reduction in HSV-2 prevalence for several decades. 
Consequently, the additional “benefit” of the CAPRISA microbicide (i.e., the effect of the 
microbicide in partially protecting against HSV-2 infection) will not substantially increase 
its impact on reducing HIV transmission over the time period of our analyses (i.e. over a 
decade).
Predictive Maps of the Cumulative Number of HIV IP
The cumulative number of HIV IP in each province, over a decade, is shown in Fig. 3; the 
predictions are based on assuming a high coverage (~90%) of the intervention. Predictions 
that are based on assuming moderate coverage (~60%) are shown in Supplementary Fig. 3. 
The predictive maps in Fig. 3 and Supplementary Fig. 3 show median values calculated 
from uncertainty analyses; see Methods. Figs 3A for women and 3B for men are based on 
assuming a high level of adherence. Figs 3C for women and 3D for men are based on 
assuming a moderate level of adherence. Both coverage and adherence determine the 
absolute number of HIV IP (Fig. 3 and Supplementary Fig. 3): the greater the coverage 
and/or the higher the adherence the more HIV IP. The histograms in the prediction maps 
show the gender-stratified prevalence of HIV in each province at the beginning of the 
rollout: prevalence in women (pink) and in men (blue). For comparison, histograms are 
scaled to the same degree in each province: province-specific prevalence levels are given in 
Supplementary Table 1.
Aggregating the results over all nine provinces, we predict that the total number of HIV IP 
over a decade in South Africa due to microbicide-based interventions would be: 580,000 
(median: IQR 500,000 to 670,000) in women and 190,000 (median: IQR 160,000 to 
230,000) in men if adherence and coverage are high; 410,000 (median: IQR 340,000 to 
490,000) in women and 136,000 (median: IQR 110,000 to 170,000) in men if adherence is 
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moderate and coverage is high; 360,000 (median: IQR 310,000 to 420,000) in women and 
110,000 (median: IQR 93,000 to 140,000) in men if adherence is high and coverage is 
moderate; 260,000 (median: IQR 210,000 to 300,000) in women and 81,000 (median: IQR 
65,000 to 100,000) in men if both adherence and coverage are moderate.
Intervention Efficiency Maps
The long-term efficiency of interventions in reducing HIV transmission shows substantial 
geographic variation throughout South Africa (Fig. 4, which is based on assuming coverage 
is high (~90%)). Long-term efficiency is defined in terms of the number of women-years on 
microbicides that are needed to prevent one HIV infection in women or one HIV infection in 
men; efficiency increases as the number of women-years needed to prevent one HIV 
infection decreases. The intervention efficiency maps in Fig. 4 show median values 
calculated from uncertainty analyses of the geospatial MT model; see Methods. Figs 4A and 
4B are based on high adherence, Figs 4C and 4D on moderate adherence; Figs 4A and 4C 
show intervention efficiency maps for women, Figs 4B and 4D for men. The maps show that 
the gender-specific intervention will reduce HIV transmission in men, as well as in women; 
although, not surprisingly microbicide-based interventions will be less efficient in reducing 
HIV transmission in men than in women. For example, in KwaZulu-Natal ~3 times more 
women-years are needed to prevent one HIV infection in men than to prevent one HIV 
infection in women. The intervention efficiency maps in Fig. 4 (based on the color-coding) 
show that the nine provinces can be classified into three groups based on the long-term 
efficiency of interventions in reducing HIV transmission in women: high long-term 
efficiency (KwaZulu-Natal, Mpumalanga, the Free State and the North West Province), 
moderate long-term efficiency (Guateng, Limpopo and the Eastern Cape) and low long-term 
efficiency (the Northern and Western Cape). Results are similar for men. The difference in 
long-term efficiency among the provinces is substantial; for example, in KwaZulu-Natal 
only ~110 women-years (median value) are needed to prevent one HIV infection in women 
whereas ~450 women-years (median value) are needed in the Western Cape (Fig. 4A).
The long-term efficiency of interventions in reducing HIV transmission decreases with 
adherence, Fig. 4. Notably, coverage (over the range 60% to 90%) has essentially no effect 
on the long-term efficiency of interventions; results shown in Fig. 4 are for high coverage 
(~90%) and those shown in Supplementary Fig. 4 are for moderate coverage (~60%).
The Pre-intervention Incidence Rate Determines Efficiency
We found that the pre-intervention HIV incidence rate determines the long-term efficiency 
of interventions in reducing HIV transmission in both women (Fig. 5) and men (Fig. 6): the 
higher the HIV incidence rate, the greater the long-term efficiency. Also the higher the 
adherence, the greater the efficiency: Figs 5A and 6A are based on high adherence, Figs 5B 
and 6B on moderate adherence. The long-term efficiency of interventions in reducing HIV 
transmission in men is substantially lower than in women, as shown by the difference in 
scale on the Y-axis between Figs 5 and 6. The color code for each of the nine provinces is 
given in the Figure Legends. Data clouds are shown as these results are generated from 
uncertainty analyses of the geospatial MT model; see Methods. Notably, the relationship 
between the pre-intervention HIV incidence rate and the long-term efficiency of 
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interventions in preventing HIV infection in both genders is highly non-linear: efficiency 
increases disproportionately with increasing incidence rates. Results in Fig. 5C show the 
relationship between the incidence rate and the long-term efficiency of interventions when 
the pre-intervention HIV incidence rate is moderate to high (3–10%); again the higher the 
adherence, the greater the efficiency (the solid red line represents high adherence, the dotted 
red line moderate adherence). If adherence is high the relationship between the number of 
women-years needed to prevent one HIV infection, y, in women and the average pre-
intervention incidence rate in women, x, can be specified by y = 1/0.00499x; see Methods. If 
adherence is moderate the relationship can be specified by y = 1/0.00361x. Fig. 5C shows, 
that under certain conditions, the long-term efficiency of interventions could be extremely 
high. For example, if interventions are rolled out in areas where HIV incidence rates in 
women are high (e.g., 10%) and adherence is high, only ~20 women-years on microbicides 
would be needed to prevent one HIV infection in women (Fig. 5C).
Estimating the Short-term Efficiency of Interventions
The short-term (i.e., in the first year of a rollout) efficiency of interventions in reducing HIV 
transmission, like the long-term efficiency (Fig. 4), shows substantial geographic variation 
throughout South Africa (Fig. 7A and 7B); short-term efficiency is defined in terms of the 
number of HIV IP per 10,000 microbicides in the first year of a rollout. The boxplots in Figs 
7A and 7B show the estimates for the short-term efficiency of interventions in reducing HIV 
incidence rates in women in each province. These results were calculated based on 
uncertainty analyses of the geospatial MT model; see Methods. The variation in the 
estimates of short-term efficiency, shown in the boxplots, is due to the uncertainty in the 
estimates of the province-specific pre-intervention HIV incidence rate in women and in the 
province-specific estimates of the average number of new sex partners per woman per year 
(see Supplementary Tables 2 and 3). Adherence has only a minor effect on short-term 
efficiency: Fig. 7A is based on high adherence, Fig. 7B on moderate adherence. Short-term 
efficiency, assuming high adherence, ranges from a high of 2.55 (median: IQR 2.31 to 2.81) 
HIV IP in women per 10,000 microbicides in Mpumalanga to a low of 0.81 (median: IQR 
0.69 to 0.92) HIV IP in women per 10,000 microbicides in the Western Cape (Fig. 7A). 
Notably, Mpumalanga and KwaZulu-Natal appear to be the provinces where the short-term 
efficiency of interventions would be the highest, and the Northern and Western Cape the 
provinces where the short-term efficiency would be the lowest. However, because there is 
considerable overlap in the within-province estimates of efficiency, the results shown in Figs 
7A and 7B cannot be used to identify the province where interventions would be the most 
efficient in the first year of a rollout or to determine a priority ranking of provinces based on 
short-term efficiency.
Ranking Provinces based on the Efficiency of Interventions
We used a probabilistic analysis in order to identify the provinces where interventions are 
most likely to have the highest efficiency in reducing HIV incidence in women in the first 
year of a rollout. To conduct this analysis we stochastically reordered the estimates of short-
term efficiency, independently for each province. Results are shown in Fig. 7C in the form 
of stacked histograms: rank 1 indicates the province where interventions would be the most 
efficient and rank 9 the province where they would be the least efficient. These results show 
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that it is most probable that interventions would be the most efficient in two provinces 
(KwaZulu-Natal and Mpumalanga), but it cannot be determined whether they would be the 
most efficient in KwaZulu-Natal or in Mpumalanga. Furthermore, it is highly probable that 
the Northern and the Western Cape are the provinces where interventions are most likely to 
be the least efficient in the first year of a rollout (Fig. 7C). The North West province is likely 
to be in 6th place and Guateng in 7th place, but the rank ordering of Limpopo, the Eastern 
Cape, and the Free State in terms of 3rd, 4th and 5th place is not clear (Fig. 7C). Notably the 
probabilistic ranking based on short-term efficiency estimates (Fig. 7C) is not exactly the 
same as the probabilistic ranking based on long-term efficiency estimates (Fig. 3). This is 
because over time (in our case, a decade) HIV incidence rates will decrease (for both 
genders), as a function of increased coverage of treatment and the effects of the intervention, 
and the long-term efficiency of interventions is a nonlinear function of the HIV incidence 
rate (Figs 5 and 6).
Ranking Provinces based on HIV Incidence Rates
We also used a probabilistic analysis to determine the geographic regions where HIV 
incidence rates in women are currently the highest; to conduct this analysis we stochastically 
reordered the estimates for HIV incidence rates, independently for each province. These 
results are shown in Fig. 7D, where rank 1 indicates the province with the highest HIV 
incidence in women and rank 9 the province with the lowest HIV incidence. These results 
show that it cannot be concluded with certainty which province has the highest HIV 
incidence rate, but that it is most probably KwaZulu-Natal. Clearly, the Northern Cape and 
the Western Cape are provinces where HIV incidence is most likely to be the lowest (Fig. 
7D). The ranking of the provinces based on estimates of HIV incidence rates is similar to the 
ranking based on estimates of the long-term efficiency of interventions. However the 
ranking of the provinces based on estimates of HIV incidence rates (Fig. 7D) is not exactly 
the same as the ranking of the provinces based on estimates of short-term efficiency (Fig. 
7C). This is because short-term efficiency depends upon both HIV incidence and the levels 
of sexual behavior (see Methods). For example, if two provinces have the same HIV 
incidence rate but women in province A have (on average) slightly more partners than 
women in province B, interventions would be more efficient in reducing HIV transmission 
in province B than in province A. If the number of sex partners were exactly the same in 
every province (and incidence rates were known with certainty) then a ranking of the 
provinces based on short-term efficiency would be the same as a ranking based on HIV 
incidence rates.
The GRAS for Implementation of the Utilitarian Rollout Plan
The GRAS for implementing the utilitarian rollout plan, under different levels of resource 
constraints, is shown by the pie charts in Figs 8A and 8B; in both charts it is assumed that 
adherence is high. These results were obtained from a single optimization analysis where it 
was assumed that there was no uncertainty in estimating province-specific pre-intervention 
HIV incidence rates in women, province-specific pre-intervention HIV prevalence levels in 
women or province-specific levels of risk behavior (see Methods); the objective of the 
optimization was to maximize the number of HIV IP throughout South Africa. Results in 
Fig. 8A are based on assuming there are 50 million microbicides to allocate in the first year 
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of the rollout, this is enough for 35% of the 15–49 year old HIV-negative women in South 
Africa. Results in Fig. 8B are based on assuming there are 100 million microbicides to 
allocate, this is enough for 65% of the 15–49 year old HIV-negative women in South Africa. 
The optimization results show that under the utilitarian plan interventions should only be 
allocated to two of the nine provinces: Mpumalanga and KwaZulu-Natal (Figs 8A and 8B). 
Therefore the optimal geographic location to rollout the utilitarian plan is in these two 
provinces. Mpumalanga and KwaZulu-Natal are the provinces where it is most probable that 
interventions would be the most efficient in reducing HIV incidence in women (Fig. 7C), 
and where HIV incidence in women is likely to be the highest (Fig. 7D). Similar results are 
obtained if adherence is moderate (Supplementary Fig. 5).
The GRAS for implementing the utilitarian rollout plan, given 50 million microbicides, is to 
give 56% to Mpumalanga and 44% of the supply to KwaZulu-Natal (Fig. 8A). The GRAS 
for implementing the utilitarian rollout plan, given 100 million microbicides, is to give 72% 
of the supply to KwaZulu-Natal and 28% to Mpumalanga (Fig. 8B). When only 50 million 
microbicides are available there are not enough microbicides to give them to all the HIV-
negative women who want them in both Mpumalanga and KwaZulu-Natal. Because it is 
slightly more probable that interventions will be more efficient in the first year of a rollout 
in Mpumalanga than KwaZulu-Natal (Fig. 7C), the optimization algorithm first allocates the 
available resources to Mpumalanga to provide to all the women who want them and then 
allocates the remaining resources to KwaZulu-Natal. Consequently, under this level of 
resource constraint Mpumalanga receives slightly more of the available resources than 
KwaZulu-Natal. However when 100 million microbicides are available, Mpumalanga still 
receives the same number of microbicides (i.e., enough to provide to all the women who 
want them), but there are now many more leftover to give to KwaZulu-Natal. Consequently, 
under this level of resource constraint, KwaZulu-Natal receives more of the available 
resources than Mpumalanga.
The GRAS for Implementation of the Egalitarian Rollout Plan
The egalitarian plan is implemented by using a proportional GRAS; this is the conventional 
approach for sharing a limited supply of resources, and it results in the same coverage level 
in every province. Using the proportional GRAS, the proportion of the supply given to each 
province is equal to the number of HIV-negative women living in that province divided by 
the total number of HIV-negative women in South Africa. This GRAS is shown by the pie 
chart in Fig. 8C that shows that the resources should be shared among all nine provinces. 
The percentage of the supply of microbicides that should be given to each province ranges 
from 2% (for the Northern Cape) to 21% (for Guateng province). These results show that 
interventions should be rolled out, simultaneously, in all nine provinces. Notably, the GRAS 
for the egalitarian plan only depends upon the geographic distribution of the population of 
HIV-negative women in South Africa; it does not depend upon the level of resource 
constraints. If there were no resource constraints, the GRAS for implementing the utilitarian 
rollout plan would be the same as the GRAS for the egalitarian plan.
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Number of HIV IP under the Utilitarian or Egalitarian Plan
If 50 million microbicides are available and adherence is high, using the GRAS for the 
utilitarian plan (shown in Fig. 8A) would prevent 41% more HIV infections in South Africa 
in the first year of the rollout than the egalitarian plan: ~14,100 HIV IP versus ~10,000 HIV 
IP. If the same number of microbicides are available and adherence is moderate, using the 
GRAS for the utilitarian plan (shown in Supplementary Fig. 5A) would prevent ~40% more 
HIV infections in South Africa in the first year of the rollout than the egalitarian plan: 
~12,800 HIV IP versus ~9,200 HIV IP. If 100 million microbicides are available and 
adherence is high, using the GRAS for the utilitarian plan (shown in Fig. 8B) would prevent 
~38% more HIV infections in South Africa in the first year of the rollout than the egalitarian 
plan: ~27,500 HIV IP versus ~20,000 HIV IP. If the same number of microbicides are 
available and adherence is moderate, using the GRAS for the utilitarian plan (shown in 
Supplementary Fig. 5B) would prevent ~34% more HIV infections in South Africa in the 
first year of the rollout than the egalitarian plan: ~24,600 HIV IP versus ~18,400 HIV IP.
Including Uncertainty when Designing Rollout Plans
Results from multiple (1,362 were conducted, see Methods) optimization analyses that 
include uncertainty in the province-specific estimates of the pre-intervention HIV incidence 
rates in women, the pre-intervention HIV prevalence levels in women and the levels of risk 
behavior are shown in Table 1. In these analyses the rank ordering of the provinces, in terms 
of HIV incidence rates in women, was varied probabilistically. Each optimization analysis 
calculated the GRAS necessary for implementing the utilitarian plan, and identified the 
optimal location for initiating the rollout in terms of a combination of two provinces. It was 
assumed that 50 million microbicides would be available. The combinations that occurred 
most frequently from the multiple optimization analyses are shown in Table 1. The most 
frequent combination was Mpumalanga and KwaZulu-Natal; the same two provinces that 
were identified in the initial optimization analysis that did not include uncertainty. However, 
this specific combination was only found in 37% of the optimizations; this occurred because 
it is not certain in which of several provinces interventions would be the most efficient in 
reducing HIV incidence in women (Fig. 7C). Our results show it cannot be concluded with 
certainty that Mpumalanga and KwaZulu-Natal are the optimal combination of provinces to 
begin the rollout, but it should be noted that this combination occurred twice as frequently as 
the next most frequent two-province combination (Table 1).
In all of the optimization analyses rolling out interventions using the utilitarian plan 
prevented substantially more HIV infections in women in the first year of the rollout than 
using the egalitarian plan. However due to the uncertainty in parameter estimation, the 
results show fairly wide variation in terms of the allocation of resources between 
Mpumalanga and KwaZulu-Natal (i.e., in the GRAS necessary for implementing the 
utilitarian plan), Table 1. Even when Mpumalanga and KwaZulu-Natal are identified as the 
optimal two provinces to begin the rollout there is fairly wide variation in the GRAS. This is 
because in ~50% of the optimizations Mpumalanga was identified as the province where 
interventions would be the most efficient in the first year of the rollout in reducing HIV 
incidence rates in women (Fig. 7C) and was therefore allocated the largest proportion of 
resources, and in ~50% KwaZulu-Natal was identified as the province where short-term 
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efficiency would be the highest (Fig. 7C) and was therefore allocated the largest proportion 
of resources. In addition, KwaZulu-Natal is a much larger province than Mpumalanga; 
consequently our results show that (given uncertainty in province-specific pre-intervention 
HIV incidence estimates in women, province-specific pre-intervention HIV prevalence 
levels in women, and province-specific levels of risk behavior), on average, slightly more 
resources should be allocated to KwaZulu-Natal than to Mpumalanga. In contrast the initial 
optimization analysis, that did not include uncertainty, could only calculate a single GRAS. 
Since this was based on identifying Mpumalanga as the province where interventions would 
be most efficient, the GRAS was to allocate slightly more of the resources to Mpumalanga 
than to KwaZulu-Natal.
Although our results from the multiple optimization analyses show fairly wide variation in 
the GRAS, our results show much lower variation in the outcome in terms of the benefit of 
the utilitarian plan in comparison with the egalitarian plan. Specifically, in terms of the 
percentage increase in HIV IP in women by the utilitarian plan in comparison with the 
egalitarian plan (Table 1). There is less variation in the benefit because the short-term 
efficiency of interventions is likely to be very similar in Mpumalanga and KwaZulu-Natal 
(Fig. 7C); consequently the GRAS for the utilitarian plan (over the identified range in Table 
1) has relatively little effect on the additional number of HIV IP. If adherence is moderate 
the benefit of the utilitarian plan in comparison with the egalitarian plan is slightly less than 
when adherence is high (Table 1). Notably, the results from the initial optimization analysis 
for the benefits of the utilitarian plan in comparison with the egalitarian plan are within the 
Inter-Quartile Ranges obtained from the multiple optimization analyses (Table 1).
Results in Fig. 9 are from the multiple optimization analyses which include uncertainty in 
parameter estimation when calculating both the utilitarian and egalitarian strategy, see 
Methods. In both Fig. 9A and 9B the results for the utilitarian strategy are based on 
assuming that the optimal implementation plan is to divide resources between KwaZulu-
Natal and Mpumalanga; the range for the GRAS that is used is shown in Table 1. Fig. 9A 
shows the number of HIV IP in women in each province in the first year of the rollout, 
assuming 50 million microbicides are available: grey data show the results of the egalitarian 
plan (solid grey columns based on high adherence, striped grey columns on moderate 
adherence) and red data show the results of the utilitarian plan (solid red columns based on 
high adherence, striped red columns on moderate adherence). The results in Fig. 9B are 
qualitatively similar to those shown in Fig. 9A; but they are quantitatively different as they 
are based on assuming 100 million microbicides are available. Clearly, HIV infections 
would be prevented in only two provinces if the utilitarian rollout plan is used, but in every 
province if the egalitarian plan were used. Not surprisingly, regardless of whether the rollout 
plan is based on the utilitarian or the egalitarian principle, the greater the resource 
constraints and/or the lower the adherence the fewer the number of HIV IP (Fig. 9A and 
9B).
Discussion
Governments in Sub-Saharan African countries may soon have to decide how best to roll out 
interventions in order to control their HIV epidemics. Our results show that the resource 
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allocation decisions that are made at the beginning of a rollout, and the geographic location 
where the rollout is initiated, will be crucial in determining the success of interventions on 
reducing HIV incidence rates. We have compared two different types of strategies for 
rolling out interventions: one (the utilitarian strategy) maximizes the number of HIV IP by 
using geographic targeting, and the other (the egalitarian strategy) maximizes geographic 
equity in access to the available resources. Notably, both of these strategies are based on 
ethical principles that the WHO recommends considering when deciding how to allocate 
scarce resources. We have found that using geographic targeting (at the level of the 
province) could prevent ~40% more HIV infections in the first year of the rollout than using 
the egalitarian plan. Our results show this would occur because there is considerable 
geographic variation in incidence throughout South Africa, and the efficiency of 
interventions increases disproportionately with increasing incidence. To increase the utility 
of our study, we included uncertainty in our estimates of HIV incidence rates, HIV 
prevalence levels, and levels of risk behavior when evaluating the potential benefits of 
geographic targeting (i.e., the utilitarian strategy). We also included uncertainty in the rank 
ordering of the provinces, in terms of incidence rates. Hence we obtained probabilistic 
results that can be used to inform evidence-based decision-making. The purpose of our 
analysis was not to provide quantitative results that can be used to make detailed health 
policy recommendations, but to gain insights into the potential consequences of different 
resource allocation strategies. Our results are robust in showing that using geographic 
targeting in South Africa could be an effective strategy for maximizing the impact of limited 
resources on controlling the HIV epidemic. Furthermore, our results indicate that 
microbicide-based interventions may be the most efficient in reducing HIV incidence rates 
in women in Mpumalanga and KwaZulu-Natal. Notably, we found that KwaZulu-Natal 
should receive slightly more of the resources than Mpumalanga in terms of the benefit that 
will be gained (in terms of the number of HIV IP) by using geographic targeting.
As with any modeling study, ours has limitations. We have focused on the geographic 
allocation of resources when rolling out one type of intervention and not the more complex 
problem of how to allocate resources between different HIV prevention methods; this is the 
focus of our current research. We have considered only the implementation stage of the 
rollout, the geographic allocation of resources could be changed over subsequent years as 
HIV incidence rates change and/or more resources become available 10. We have used two 
types of models for our analyses: a geospatial resource allocation model coupled with a 
geospatial meta-population transmission model. We built the geospatial resource allocation 
model using parsimonious assumptions to aid the transparency of our optimization analysis. 
The model could be made more complex and then, in combination with optimization 
analyses, used to design more detailed resource allocation strategies. These strategies could 
be designed to satisfy multiple objectives and/or further increase the efficiency of resource 
utilization by using more detailed geographic targeting strategies; this is the focus of our 
current research. A more complex resource allocation model could also be used as a 
foundation for detailed economic modeling 11–14. Notably, the geospatial meta-population 
transmission model that we have developed has a very different structure from previous 
transmission models of generalized HIV epidemics in Sub-Saharan Africa. Our novel model 
includes spatial demographics, geographic heterogeneity in HIV prevalence and incidence, 
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geographic variation in treatment coverage, and geographic variation in levels of risk 
behavior. In contrast, previous transmission models have been built on the assumption that 
the population is uniformly distributed throughout the country, and the prevalence (and 
incidence) of HIV does not vary geographically. Notably, these assumptions do not hold for 
South Africa, nor for many other Sub-Saharan African countries with generalized HIV 
epidemics; e.g., Lesotho, Botswana, Nigeria and Uganda15–18. However, we have not 
included several important factors such as age-structure, urban-rural differences, and 
migration in our geospatial meta-population transmission model; this would have required 
detailed province-specific data, which are not currently available. Increasing the complexity 
of our model would not change our qualitative results regarding the benefits of geographic 
targeting.
Several strategies are being considered for controlling HIV epidemics in Sub-Saharan 
Africa; e.g., using universal “test and treat”, rolling out ARV-based pre-exposure prevention 
tools, or circumcising millions of men. It is not clear if any of these strategies are feasible; 
nor whether more detailed strategies that are based on targeting “high-risk” 
individuals 11,19–21 or discordant couples are viable 22. The feasibility of using any type of 
prevention tool to control HIV epidemics will depend upon numerous factors including both 
acceptability and (in the case of ARV-based tools) adherence. Our results regarding 
geographic targeting are not specific to the rollout of interventions based on microbicides; 
they are generalizable to other pre-exposure prophylaxis (PrEP) based prevention 
modalities. New drug formulations or delivery systems that do not require frequent dosing 
may make PrEP more acceptable, and hence overcome some of the current challenges of 
adherence. Recent interest has focused on the development of intra-vaginal rings for topical 
ARV delivery, and on novel long-acting injectable ARV formulations that provide sustained 
systemic drug exposures but require infrequent dosing 23–26. The success of any type of 
public health intervention (e.g., voluntary male medical circumcision, PrEP, and “treatment 
as prevention”) in reducing HIV transmission will also be affected by migration, which is a 
fairly common phenomenon in Sub-Saharan Africa. Modeling studies have shown that 
migration can “spatially diffuse” the impact of an intervention; i.e., in the presence of 
migration the intervention will not be as effective in reducing transmission in the region 
where it is applied 27,28, but could potentially reduce transmission in other regions 28. The 
effect of migration on determining the success of any intervention will depend upon multiple 
variables: e.g., the percentage of the population that are migrants, migration patterns, the 
length of time migrants spend away from their primary residence and the effect of migration 
on sexual mixing patterns. With respect to microbicides, the effect of migration will also 
depend on the choices women make. Some may choose to use microbicides while they are 
away from home, others may choose not to use them. Detailed data will need to be collected 
on migration in order to inform the design of all types of interventions in the “real-world”.
We are the first to show that using the same amount of antiretrovirals but different rollout 
plans can affect the success of interventions in controlling HIV epidemics. Specifically, we 
have shown that (under resource constraints) geographic targeting could be used to 
maximize the impact of a limited supply of resources on reducing HIV transmission. Our 
results indicate that further geographic targeting within provinces (i.e., “Hot-Spots” where 
incidence rates are very high) is likely to result in an even greater efficiency in resource 
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utilization. Our qualitative findings regarding the potential utility of geographic targeting are 
likely to apply to other Sub-Saharan African countries that have geographic variation in the 
severity of their HIV epidemic; e.g., Lesotho, Botswana, Nigeria and Uganda 15–18. The 
magnitude of the difference (in terms of the number of HIV IP) between the utilitarian and 
egalitarian plan (i.e., the benefits of using geographic targeting) will depend upon the 
average incidence rate in the country, the geographic variability in incidence, and the level 
of resource constraints. The higher the overall incidence rate and/or the greater the 
geographic variability in incidence and/or the more constrained the resources, the more HIV 
infections the utilitarian rollout plan will prevent in comparison with the egalitarian plan. In 
contrast the higher the treatment coverage (hence the lower the incidence), the fewer HIV 
infections the utilitarian rollout plan will prevent in comparison with the egalitarian plan; 
this is due to the nonlinear effect of incidence on efficiency. Taken together, our results have 
great significance for global health policy. They show that - under resource constraints - it 
will not be possible to maximize the efficiency of resource utilization (and hence minimize 
incidence) and also achieve countrywide equity in access to prevention resources. Currently, 
HIV prevention resources are allocated geographically with the objective of providing 
countrywide equity in access. However, our results suggest that many more HIV infections 
could be prevented - using the same amount of resources - if other ethical principles are 
used. Using the utilitarian principle to design rollout plans based on geographic targeting 
could significantly increase our ability to control HIV epidemics in Sub-Saharan Africa.
Methods
Defining Adherence Levels and specifying Effectiveness
Efficacy is the degree of protection against infection conferred by a microbicide if adherence 
is 100%. Effectiveness is the degree of protection against infection conferred by a 
microbicide at a given level of adherence.
The HIV effectiveness results of the CAPRISA 004 trial were reported for three adherence 
levels 5. Low adherence is defined as using the microbicide in < 50% of sex acts. Moderate 
adherence is defined as using the microbicide in 50–80% of sex acts. High adherence is 
defined as using the microbicide in > 80% of sex acts. At low, moderate and high adherence 
levels the effectiveness of the microbicide in protecting against HIV infection was 28%, 
38% and 54%, respectively 5. The effectiveness of the microbicide in protecting against 
HSV-2 infection was 51% and was not stratified by adherence 5.
We defined three adherence levels (low, moderate and high) as in the CAPRISA trial and 
specified the effectiveness of the microbicide in protecting against HIV infection at each 
level based on the trial results 5. Based on the trial results, we specified the effectiveness of 
the microbicide in protecting against HSV-2 infection to be 51% at all three adherence 
levels 5.
The Geospatial Meta-population Transmission Model Structure
The geospatial meta-population transmission (MT) model includes the spatial demographics 
of South Africa, the within-country geographic variation in HIV prevalence and incidence, 
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the province-specific rollout of treatment (with coverage increasing from 2004 onwards, 
Supplementary Fig. 1) and geographic heterogeneity in sexual behavior. The model consists 
of 33 non-linear ordinary differential equations. The equations specify the transmission 
dynamics of coupled HIV and HSV-2 epidemics; the equations are given in Section C.3 of 
the Supplementary Methods.
The model includes coupled HIV and HSV-2 epidemics because each virus affects the 
transmission of the other virus 29–32. HIV infection increases the risk of transmitting 
HSV-2 29, conversely HSV-2 infection increases the risk of transmitting HIV 33. In addition, 
HSV-2 infection increases the risk of acquiring HIV 34,35. All of our analyses are based on 
the assumption the microbicide could potentially reduce both HIV and HSV-2 transmission; 
we made this assumption because the CAPRISA microbicide was found to be partially 
effective against both HIV and HSV-2 5.
The model is gender-stratified and includes susceptible individuals, individuals infected with 
only HIV, individuals infected with only HSV-2, and individuals co-infected with both HIV 
and HSV-2. The natural history of HIV is modeled as a series of three stages, characterized 
by CD4 level and viral load (which determines infectivity); HIV-infected individuals on 
treatment are also tracked. The natural history of HSV-2 is modeled as two alternating 
states: the infectious state (when individuals shed virus) and the noninfectious state (when 
the virus is latent). Individuals co-infected with both viruses are modeled to reflect 
modifications in infectivity and susceptibility due to HIV or HSV-2 infection.
The model is based on the parsimonious assumptions that there is homogeneous mixing 
within a province, and negligible (at the population level) sexual mixing among individuals 
living in different provinces. See Section C in the Supplemental Methods for further details 
on model structure, a flow diagram is given in Supplementary Fig. 6. The model was 
simulated using MATLAB.
Model Parameterization
The geospatial MT model was parameterized using demographic, behavioral and treatment 
data from South Africa; ranges were specified for each parameter. Supplementary Table 4 
provides a summary of all model parameter symbols and definitions. Parameter ranges are 
provided in Supplementary Tables 3, 5, 6 and 7. Province-specific parameters are provided 
in Supplementary Table 3. Supplementary Table 5 gives antiretroviral therapy and 
microbicide parameters. Supplementary Table 6 gives HIV parameters; Supplementary 
Table 7 gives HSV-2 parameters. Each parameter was sampled 1,500 times using Latin 
Hypercube Sampling (LHS) 36–38.
Model Calibration, Verification and Validation
The parameter set, obtained using LHS 36–38, was used for calibrating the geospatial MT 
model. Calibration was based on an iterative multi-stage procedure that includes Monte 
Carlo filtering; see Section C.5 in the Supplementary Methods. The model was calibrated for 
both women and men in each of the nine provinces for the year 2004, when HIV prevalence 
in South Africa appears to have stabilized (Supplementary Fig. 7) and treatment was 
introduced. It was calibrated by fitting to gender-stratified province-specific estimates of 
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HIV prevalence for 2004 generated by the most recent version of the Actuarial Society for 
South Africa (ASSA) AIDS and Demographic model 39. The calibration resulted in 1,362 
estimates for gender-stratified HIV incidence rates and prevalence levels for each of the nine 
provinces for the year 2004. After the model was calibrated, it was verified (see Section C.6 
in the Supplementary Methods) and validated (see Section C.7 in the Supplementary 
Methods).
Multivariate Sensitivity Analysis
We used response hypersurface modeling and LHS 36–38 to conduct multivariate sensitivity 
analyses of the geospatial MT model 36, 40. We determined the effect of microbicide 
coverage and effectiveness on reducing HIV and HSV-2 transmission in both genders over a 
decade in KwaZulu-Natal province. Coverage is defined as the percentage of women who 
are uninfected with HIV (regardless of whether they are infected with HSV-2) and who use 
the microbicide. We used the 1,362 simulations that had been calibrated to 2004; we 
introduced province-specific treatment rollout (Supplementary Fig. 1), ran the simulations to 
the current year and then introduced microbicide-based interventions. The parameter values 
used are specific to KwaZulu-Natal; see Supplementary Table 3. The rollout of microbicides 
was modeled for 10 years; see Section C.2 in Supplementary Methods and Supplementary 
Fig. 8. Throughout this time we also modeled the planned continued expansion of treatment; 
see Section C.1 in the Supplementary Methods and Supplementary Fig. 1. We varied 
microbicide coverage rates from 30–90%, HIV effectiveness from 15–75% and HSV-2 
effectiveness from 30–75%. The reduction in HIV and HSV-2 transmission due to 
microbicides, over a decade, was calculated. Response hypersurfaces were then fitted to 
these results.
Scenario Analyses
We conducted scenario analyses of the geospatial MT model to examine the effect of 
microbicide coverage and effectiveness on reducing HIV and HSV-2 transmission in 
KwaZulu-Natal province where the CAPRISA 004 trial was conducted; parameter values 
are given in Supplementary Table 3. The six scenarios are based on different assumptions 
regarding coverage (60% or 90%) and adherence (low, moderate or high). Low, moderate 
and high adherence corresponds to an effectiveness of the microbicide in protecting against 
HIV infection of 28%, 38% and 54%, respectively. In all six scenarios the effectiveness of 
the microbicide in protecting against HSV-2 infection is 51%. The remaining parameter 
values used to generate the scenarios are the median values of the distributions shown in 
Supplementary Tables 3, 5, 6 and 7.
Uncertainty Analyses
We conducted four uncertainty analyses of the geospatial MT model. These analyses were 
based on: (i) high coverage (90%) and high adherence, (ii) high coverage (90%) and 
moderate adherence, (iii) moderate coverage (60%) and high adherence, and (iv) moderate 
coverage (60%) and moderate adherence. The adherence-effectiveness relationship we 
modeled was determined from the results of the CAPRISA trial 5. To model high adherence, 
we used a triangular distribution for effectiveness against HIV ranging from 34%–74% with 
a peak density at 54% 5. To model moderate adherence, we used a triangular distribution for 
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effectiveness against HIV ranging from 18%–58% with a peak density at 38% 5. For all four 
uncertainty analyses, we used a triangular distribution for effectiveness against HSV-2 
ranging from 31%–71% with a peak density at 51% 5.
For each uncertainty analysis, and for each of the nine provinces, we used the 1,362 
simulations that had been obtained from the calibration procedure. The model had been 
calibrated to 2004 when the rollout of treatment began in South Africa. Therefore, we 
introduced treatment into each of the simulations beginning in 2004. We used different 
treatment rollout rates in each province; see Section C.1 of the Supplementary Methods and 
Supplementary Fig. 1. We continued modeling the roll out of treatment in each province to 
the current year at which point we introduced interventions. Therefore we had 1,362 
estimates for the gender-stratified pre-intervention HIV incidence rates and prevalence 
levels in each province. The GRAS for the egalitarian rollout plan was used to divide the 
available supply of microbicides among the nine provinces. The proportion of the supply 
that each province was allocated equaled the number of HIV-negative women who live in 
the province divided by the total number of HIV-negative women who live in SA. The 
modeling of the rollout of microbicides is described in Section C.2 of the Supplementary 
Methods, and shown in Supplementary Fig. 8. When conducting the uncertainty analyses, as 
well as the historical rollout of treatment beginning in 2004, we included the planned 
province-specific expansion of treatment; see Section C.1 of the Supplementary Methods 
and Supplementary Fig. 1
Predictive Maps of the Cumulative Number of HIV IP
We used the uncertainty analyses to predict the cumulative number of HIV IP (over a 
decade) by interventions in each province. When we made predictions we excluded the 
effect of expanding treatment coverage on reducing transmission. This was accomplished by 
running each scenario in each uncertainty analysis twice: once with interventions and 
expanding treatment coverage, and once with only expanding treatment coverage. The 
difference between the two scenarios is the number of HIV IP by microbicide-based 
interventions. Results from these analyses were then mapped.
Intervention Efficiency Maps
Predictions generated by the uncertainty analyses were used to calculate the long-term (i.e., 
over a decade) efficiency of interventions in reducing HIV transmission in both genders in 
each province; the results were then mapped. Long-term efficiency was defined as the 
number of women-years on microbicide needed to prevent one HIV infection in either 
gender. Women-years were calculated by multiplying the number of women using 
microbicides each year with the number of years of microbicide usage.
Pre-intervention Incidence Rate and Long-term Efficiency
Predictions generated by the uncertainty analyses were plotted and used to identify a 
statistical relationship between the pre-intervention HIV incidence rate in women and the 
long-term efficiency of interventions in reducing HIV transmission in both genders. We also 
conducted regression analyses to determine the value of y: where y represents the median 
number of women-years necessary to prevent one HIV infection in women. We determined 
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the value of y assuming either high or moderate adherence. Based on data from the 
CAPRISA trial5 we assume high adherence corresponds to using microbicides in 85% of sex 
acts and moderate adherence to using microbicides in 65% of sex acts.
Short-term Efficiency of Interventions
The predictions generated by the uncertainty analyses were used to calculate the short-term 
efficiency of interventions (i.e., the efficiency in the first year of the rollout) in each 
province. Short-term efficiency was defined as the number of HIV IP per 10,000 
microbicides used. This equals 10,000/2ycau where y represents the median number of 
women-years necessary to prevent one HIV infection in women and 2cau is the total number 
of microbicides used (on average) per year by each woman. In the expression 2cau, c is the 
average number of new sex partners per woman per year, a the number of sex acts per 
partnership and u the proportion of sex acts for which microbicides are used according to the 
CAPRISA 004 protocol (i.e., u represents adherence). Since the protocol was based on using 
a microbicide before and after sex 5, the factor 2 is included in the equation. We calculated 
the short-term efficiency of interventions in each province by using province-specific values 
for y and c. We calculated province-specific estimates of y by dividing the number of HIV 
IP by the number of women-years on microbicide for each of the 1,362 simulations. 
Province-specific values for c were estimated during the calibration of the geospatial MT 
model; the range is given in Supplementary Table 3. The range of estimates for a is given in 
Supplementary Table 6. We calculated short-term efficiency of interventions assuming 
either high or moderate adherence. Based on data from the CAPRISA trial 5, we assume 
high adherence corresponds to using microbicides in 85% of sex acts and moderate 
adherence to using microbicides in 65% of sex acts.
Structure of the Geospatial Resource Allocation Model
The geospatial resource allocation (RA) model was based on the parsimonious assumption 
that, over one year, HIV prevalence does not change substantially and the number of HIV IP 
in men (due to women using microbicides) would be negligible. The model operates under 
two constraints: the total number of microbicides that are available in the first year of the 
rollout (i.e., the amount of resources) and adherence.
Model Parameterization
The geospatial RA model was parameterized using province-specific estimates for the 
number of 15–49 year old HIV-negative women residing in the province, the average 
number of new sex partners per woman per year, and the pre-intervention HIV incidence 
rate in women. The number of 15–49 year old HIV-negative women in each province was 
calculated by multiplying the total number of 15–49 year old women in the province with 
the proportion of women in that province that are not infected (i.e, one minus the pre-
intervention HIV prevalence level). The total number of 15–49 year old women in each 
province was based on estimates from the most recent version of the ASSA AIDS and 
Demographic model 39. Ranges for province-specific estimates for the average number of 
new sex partners per woman per year were obtained from the calibration of the geospatial 
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MT model. Pre-intervention HIV incidence rates and prevalence levels were obtained from 
the uncertainty analyses of the geospatial MT model.
Estimating the GRAS for the Egalitarian Rollout Plan
Under the egalitarian rollout plan the supply of resources (i.e., microbicides) is divided 
among the nine provinces in proportion to the number of women in need of protecting 
against HIV infection. Specifically, the percentage of the supply that a province is allocated 
is equal to the number of 15–49 year old HIV-negative women who live in that province 
divided by the total number of HIV-negative women (in the same age group) who live in 
SA. For each province, we calculated the number of HIV-negative women in the province 
by multiplying the number of 15–49 year old women in the province 39 with the proportion 
of women in that province that are not infected (i.e, one minus the pre-intervention HIV 
prevalence level). The total number of 15–49 year old women in each province was based 
on estimates generated by the most recent version of the ASSA AIDS and Demographic 
model 39. We calculated a GRAS for the egalitarian plan that included uncertainty in 
estimating the pre-intervention HIV prevalence levels in women, and another without 
uncertainty. To include uncertainty we used province-specific ranges for the pre-intervention 
HIV prevalence levels obtained from the uncertainty analyses of the geospatial MT model. 
To calculate the GRAS for the egalitarian plan without uncertainty we used the median 
value of the range for each province.
Calculating the number of HIV IP by the Egalitarian Plan
The number of HIV infections prevented in each of the nine provinces (under the egalitarian 
plan) is calculated as the product of the number of HIV-negative women (aged 15–49 years 
old) who reside in that province, the pre-intervention incidence rate in that province, the 
proportion of HIV-negative women (in that province) who use microbicides, and the 
effectiveness of the microbicide. Summing over all provinces gives the total number of HIV 
IP.
Optimization without Uncertainty in Parameter Estimation
Throughout our description of the optimization analyses when we refer to women we are 
referring to women who are 15–49 years old. We used the geospatial RA model and 
mathematical optimization techniques based on linear programming to calculate (under 
resource constraints) the GRAS that is necessary to implement the utilitarian rollout plan, 
the optimal geographic location to initiate a rollout based on the utilitarian principle, and the 
number of HIV IP in women in the first year of the rollout. We used the total number of 
HIV IP in women in South Africa as the objective function for the optimization analysis, 
and specified the resource constraint in terms of the total number of microbicides available 
in the first year of the rollout. The optimal solution is the GRAS that maximizes the total 
number of HIV IP in South Africa in the first year of the rollout; i.e., it is the GRAS for the 
utilitarian rollout plan. As the geospatial RA model considers only the first year of the 
rollout, the province(s) that are allocated resources in the optimal solution are the optimal 
geographic location(s) to initiate the rollout.
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The optimization algorithm allocates the available resources disproportionally to the 
provinces where interventions are the most efficient; i.e., to the provinces that prevent the 
highest number of HIV infections for a given amount of resources. The efficiency of 
interventions in a province is equal to the number of HIV IP in that province in the first year 
of the rollout divided by the total number of microbicides used in that province. The number 
of HIV IP in each province, given a specific proportion of the supply of microbicides, is 
calculated as the product of the number of HIV-negative women who reside in the province, 
the HIV incidence rate in the absence of microbicides, the proportion of HIV-negative 
women who use microbicides, and the level of adherence (which specifies the degree of 
effectiveness of the microbicide in protecting against HIV). The total number of 
microbicides used in each province is calculated as the product of the number of HIV-
negative women who reside in that province, the proportion of these women who use 
microbicides, the average number of new sex partners per woman per year, and twice the 
average number of sex acts per partnership. We assume women will use microbicides 
according to the CAPRISA004 protocol (i.e. once before and after sex 5). The optimization 
algorithm identifies the GRAS that would maximize the number of HIV IP in SA in the first 
year of a rollout. The optimization problem can be stated as the following linear program:
where
Ni = number of women who reside in the ith province,
Pi = HIV prevalence in women in the ith province at the beginning of the rollout,
Ii = pre-intervention HIV incidence rate in women in the ith province,
p = effectiveness of the microbicide in protecting against HIV infection,
xi = proportion of eligible women in the ith province that receive microbicides in the 
first year of the rollout,
ci = average number of new sex partners per woman per year in the ith province,
a = average number of sex acts per partnership for women,
u = adherence level,
Y = total number of microbicides available in SA in the first year of the rollout (i.e., 
resource constraint).
For each of the nine provinces, we used the parameter set (out of the 1,362 parameter sets 
obtained from calibrating the model) that generated the median value for the incidence rate. 
With these nine parameter sets, we used the geospatial MT model to calculate - for each 
province - the number of 15–49 year old women living in that province at the beginning of 
the rollout, the pre-intervention HIV prevalence level in women, the pre-intervention HIV 
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incidence rate in women and the average annual number of new sex partners (Ni,Pi,Ii and ci 
for i = 1..9, respectively). The x term is the result of the optimization, it specifies the 
proportion of eligible women in each province that receive microbicides in the first year of 
the rollout in order to maximize the total number of HIV IP in SA in the first year of the 
rollout. Hence it specifies the GRAS for the utilitarian rollout plan.
We calculated the GRAS under two levels of resource constraints, assuming either 50 or 100 
million microbicides were available. Fifty million is enough for ~33%, and 100 million for 
~66%, of the 15–49 year old HIV-negative women in SA. For each level of resource 
constraint we conducted two analyses, assuming either high or moderate adherence. Based 
on data from the CAPRISA trial 5, we assume high adherence corresponds to using 
microbicides in 85% of sex acts (resulting in an effectiveness against HIV infection of 54%) 
and moderate adherence to using microbicides in 65% of sex acts (resulting in an 
effectiveness against HIV infection of 38%).
Optimization including Uncertainty in Parameter Estimation
We also conducted multiple (1,362) optimization analyses that included uncertainty in 
estimating the values of the province-specific pre-intervention HIV incidence rates in 
women, the pre-intervention HIV prevalence levels in women, and the average number of 
new sex partners per woman per year. We also included uncertainty in the number of sex 
acts per partnership. We included uncertainty by using parameter ranges. We used province-
specific ranges for the pre-intervention HIV incidence rates and prevalence levels obtained 
from the uncertainty analyses of the geospatial MT model. Province-specific ranges for the 
average number of new sex partners per woman per year are given in Supplementary Table 
3. The range for the average number of sex acts per partnership is given in Supplementary 
Table 6. In each of the optimization analyses the rank ordering of the provinces, in terms of 
incidence rates in women, was varied probabilistically.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Results of a multivariate sensitivity analysis of the geospatial meta-population 
transmission model
Response hypersurfaces show the cumulative percentage of HIV infections prevented in 
KwaZulu-Natal (after 10 years of a microbicide-based intervention) as a function of the 
effectiveness of the microbicide against HIV and coverage for (A) women and (B) men. 
Response hypersurfaces show the cumulative percentage of HSV-2 infections prevented in 
KwaZulu-Natal (after 10 years of a microbicide-based intervention) as a function of the 
effectiveness of the microbicide against HIV and coverage for (C) women and (D) men.
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Figure 2. Temporal effect of the effectiveness of the microbicide against HIV and coverage on 
reducing HIV and HSV-2 transmission in KwaZulu-Natal
Temporal scenarios for the cumulative percentage of HIV IP are shown for (A) women and 
(B) men. Temporal scenarios for the cumulative percentage of HSV-2 IP are shown for (C) 
women and (D) men. Blue, green and red curves depict scenarios with high, moderate and 
low adherence to microbicides. Note, colors overlap for C and D. These adherence levels 
correspond to an effectiveness level in protecting against HIV infection of 54%, 38% and 
28% (as in the CAPRISA 004 trial 5). An effectiveness of 51% in protecting against HSV-2 
infection, as found in the CAPRISA 004, is assumed for all of the scenarios. The solid and 
dashed curves depict scenarios where microbicide coverage is 90% and 60%, respectively.
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Figure 3. Prediction maps of the number of HIV infections prevented (IP) in South Africa after a 
decade of microbicide-based interventions
The white area (within the country) represents the Kingdom of Lesotho. Pink and blue bars 
indicate the HIV prevalence in women and men, respectively, in each province at the 
beginning of the intervention. The maps show the median values of the number of HIV IP in 
women (A) and (C) or men (B) and (D). The estimates are based on the results of 
uncertainty analyses of the geospatial meta-population transmission model; in these analyses 
microbicide coverage reaches ~90%. To generate A and B it was assumed the effectiveness 
of the microbicide in protecting against HIV infection was high (median value: 54%), to 
generate C and D it was assumed the effectiveness of the microbicide was moderate (median 
value: 38%); the adherence-effectiveness relationship is based on data from the CAPRISA 
004 trial 5. In A-D the effectiveness of the microbicide in protecting against HSV-2 infection 
is 51% (median value) 5.
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Figure 4. Intervention efficiency maps for microbicide-based interventions in South Africa
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The white area (within the country) represents the Kingdom of Lesotho. Pink and blue bars 
indicate the HIV prevalence in women and men, respectively, in each province at the 
beginning of the intervention. The maps show the median values of the number of women-
years on microbicides that would be necessary to prevent one HIV infection in women (A) 
and (C) or men (B) and (D). The estimates are based on the results of uncertainty analyses 
of the geospatial meta-population transmission model; in these analyses microbicide 
coverage reaches ~90%. To generate A and B it was assumed the effectiveness of the 
microbicide in protecting against HIV infection was high (median value: 54%), to generate 
C and D it was assumed the effectiveness of the microbicide was moderate (median value: 
38%); the adherence-effectiveness relationship is based on data from the CAPRISA 004 
trial 5. In A–D the effectiveness of the microbicide in protecting against HSV-2 infection is 
51% (median value) 5.
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Figure 5. Estimates of the province-specific long-term (i.e., over a decade) efficiency of 
microbicide-based interventions in reducing HIV transmission in women
Long-term efficiency is shown in terms of the number of women-years on microbicides that 
would be necessary to prevent one HIV infection in women. Long-term efficiency increases 
as the number of women-years needed to prevent one HIV infection decreases. Estimates are 
based on the results of an uncertainty analysis of the geospatial meta-population 
transmission model. (A) Results are based on assuming high adherence (where high 
adherence is defined as in the CAPRISA trial 5,9; i.e., microbicides are used in >80% of sex 
acts). (B) Results are based on assuming moderate adherence (where moderate adherence is 
defined as in the CAPRISA trial 5,9; i.e., microbicide are used in 50–80% of sex acts). Color 
codes shown in (A) and (B) represent: Mpumalanga (green), Eastern Cape (red), KwaZulu-
Natal (black), Limpopo (cyan), Free State (red), North West (yellow), Northern Cape 
(magenta), Gauteng (pink) and the Western Cape (gray). (C) Estimated number of women-
years on microbicides that would be necessary to prevent one HIV infection in women 
living in areas where incidence in women is moderate to high when the rollout begins; 
assuming either high adherence (solid red line) or moderate adherence (dotted red line).
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Figure 6. Estimates of the province-specific long-term (i.e., over a decade) efficiency of 
microbicide-based interventions in reducing HIV transmission in men
Long-term efficiency is shown in terms of the number of women-years on microbicides that 
would be necessary to prevent one HIV infection in men. Long-term efficiency increases as 
the number of women-years needed to prevent one HIV infection decreases. Estimates are 
based on the results of an uncertainty analysis of the geospatial meta-population 
transmission model. (A) Results are based on assuming high adherence (where high 
adherence is defined as in the CAPRISA trial 5,9; i.e., microbicides are used in >80% of sex 
acts). (B) Results are based on assuming moderate adherence (where moderate adherence is 
defined as in the CAPRISA trial 5,9; i.e., microbicide are used in 50–80% of sex acts). Color 
codes shown in (A) and (B) represent: Mpumalanga (green), Eastern Cape (red), KwaZulu-
Natal (black), Limpopo (cyan), Free State (red), North West (yellow), Northern Cape 
(magenta), Gauteng (pink) and the Western Cape (gray).
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Figure 7. Estimated short-term efficiency of microbicide-based interventions in reducing HIV 
transmission and rankings of provinces
The boxplots in (A) and (B) show the estimated number of HIV infections prevented in 
women per 10,000 microbicides in each of the nine provinces in the first year of a rollout 
(i.e., short-term efficiency); (A) is based on high adherence, (B) on moderate adherence. The 
results for A and B were obtained from an uncertainty analysis of the geospatial meta-
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population transmission model. Province abbreviations in (A) and (B): Mpumalanga (MP), 
KwaZulu-Natal (KZN), Limpopo (LP), Eastern Cape (EC), Free State (FS), North West 
(NW), Gauteng (GP), Northern Cape (NC), and the Western Cape (WC). The black lines 
represent median values; the grey rectangles delimit the Inter-Quartile Range. The stacked 
histograms in (C) show the probability of the priority ranking for provinces based on a 
probabilistic analysis of the short-term efficiency estimates shown in A. The stacked 
histograms in (D) show the probability of the priority ranking for provinces based on a 
probabilistic analysis of the estimated pre-intervention HIV incidence rates estimated from 
the geospatial meta-population transmission model. Color codes in C and D represent: 
Mpumalanga (red), Eastern Cape (purple), KwaZulu-Natal (blue), Limpopo (green), Free 
State (orange), North West (yellow), Northern Cape (pink), Gauteng (brown) and the 
Western Cape (gray).
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Figure 8. The geographic resource allocation strategy (GRAS) for three rollout plans
The GRAS is shown (in the form of a pie chart) in terms of the proportion of the supply of 
microbicides that need to be allocated to each province in the first year of the rollout; all 
three plans are based on high adherence. The chart in (A) shows the GRAS that is necessary 
for the implementation of a utilitarian plan if 50 million microbicides are available (enough 
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for ~33% of the 15–49 year old HIV-negative women in South Africa). The chart in (B) 
shows the GRAS that is necessary for the implementation of a utilitarian plan if 100 million 
microbicides are available (enough for ~66% of the 15–49 year old HIV-negative women in 
South Africa). The chart in (C) shows the GRAS that is necessary to implement the 
egalitarian rollout plan; it is the same whether 50 or 100 million microbicides are available. 
For (A), (B) and (C) the province abbreviations are: Mpumalanga (MP), KwaZulu-Natal 
(KZN), Limpopo (LP), Eastern Cape (EC), Free State (FS), North West (NW), Gauteng 
(GP), Northern Cape (NC), and the Western Cape (WC).
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Figure 9. A comparison of the number of HIV infections prevented by the utilitarian and the 
egalitarian strategy
The histograms in (A) show the number of HIV infections prevented in women in each 
province, in the first year of the rollout, assuming 50 million microbicides are available: 
grey data show the results of the egalitarian plan (solid grey columns based on high 
adherence, striped grey columns on moderate adherence) and red data show the results of the 
utilitarian plan (solid red columns based on high adherence, striped red columns on 
moderate adherence). The histograms in (B) are similar to those in A, but are based on a 
supply of 100 million microbicides. In both A and B the results for the egalitarian strategy 
are based on the assumption that Mpumalanga and KwaZulu-Natal are the optimal two-
province combination to use for geographic targeting (see Table 1). Province abbreviations: 
Mpumalanga (MP), KwaZulu-Natal (KZN), Limpopo (LP), Eastern Cape (EC), Free State 
(FS), North West (NW), Gauteng (GP), Northern Cape (NC), and the Western Cape (WC).
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